[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100409050":3},{"organization":4,"armGroups":7,"interventions":54,"overallOfficials":86,"centralContacts":90,"locations":95,"responsibleParty":476,"collaborators":60,"id":478,"slug":479,"hasResults":480,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":480,"sex":486,"minAge":487,"maxAge":60,"enrollmentInfo":488,"targetDuration":60,"studyType":491,"phases":492,"briefSummary":494,"conditions":495,"keywords":499,"overallStatus":112,"whyStopped":60,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":510},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14,19,25,29,33,38,42,45,50],{"label":9,"type":10,"description":11,"interventionNames":12},"1A Monotherapy Dose Escalation","EXPERIMENTAL","PF-07248144 Monotherapy Escalation",[13],"Drug: PF-07248144",{"label":15,"type":10,"description":16,"interventionNames":17},"1B Combination Dose Escalation","PF-07248144 with Fulvestrant Combination Dose Escalation",[13,18],"Drug: Fulvestrant",{"label":20,"type":10,"description":21,"interventionNames":22},"1C Combination Dose Escalation","PF-07248144 with Letrozole + Palbociclib Combination Dose Escalation",[13,23,24],"Drug: Letrozole","Drug: Palbociclib",{"label":26,"type":10,"description":27,"interventionNames":28},"2A Monotherapy Dose Expansion Arm","PF-07248144 Monotherapy Dose Expansion",[13],{"label":30,"type":10,"description":31,"interventionNames":32},"2B Combination Dose Expansion Arm","PF-07248144 with Fulvestrant Dose Expansion",[13,18],{"label":34,"type":10,"description":35,"interventionNames":36},"1D Combination Dose Escalation","PF-07248144 with PF-07220060 +Fulvestrant",[13,18,37],"Drug: PF-07220060",{"label":39,"type":10,"description":40,"interventionNames":41},"2D Combination Dose Expansion Arm","PF-07248144 with PF-07220060 +Fulvestrant Dose Expansion",[13,18,37],{"label":43,"type":10,"description":27,"interventionNames":44},"China Monotherapy Dose Expansion",[13],{"label":46,"type":10,"description":47,"interventionNames":48},"1E Combination Dose Escalation","PF-07248144 with Vepdegestrant Combination Dose Escalation",[13,49],"Drug: PF-07850327, ARV-471, vepdegestrant",{"label":51,"type":10,"description":52,"interventionNames":53},"2E Combination Dose Expansion Arm","PF-07248144 with Vepdegestrant Combination Dose Expansion",[13,49],[55,61,67,72,78,82],{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"DRUG","PF-07248144","KAT6 Inhibitor",[9,15,20,34,46,26,30,39,51,43],null,{"type":56,"name":62,"description":63,"armGroupLabels":64,"otherNames":65},"Fulvestrant","Endocrine Therapy",[15,34,30,39],[66],"Faslodex",{"type":56,"name":68,"description":63,"armGroupLabels":69,"otherNames":70},"Letrozole",[20],[71],"Femara",{"type":56,"name":73,"description":74,"armGroupLabels":75,"otherNames":76},"Palbociclib","CDK4\u002F6 Inhibitor",[20],[77],"Ibrance",{"type":56,"name":79,"description":80,"armGroupLabels":81,"otherNames":60},"PF-07220060","CDK4 inhibitor",[34,39],{"type":56,"name":83,"description":84,"armGroupLabels":85,"otherNames":60},"PF-07850327, ARV-471, vepdegestrant","PROTAC (PROteolysis Targeting Chimera) ER degrader",[46,51],[87],{"name":88,"affiliation":5,"role":89},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[91],{"name":88,"role":92,"phone":93,"phoneExt":60,"email":94},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[96,110,121,126,135,145,150,156,161,171,181,190,195,200,210,220,229,234,240,249,258,267,277,283,295,305,315,324,333,343,355,365,375,380,390,402,412,422,427,438,448,454,460,470],{"facility":97,"status":98,"city":99,"state":100,"zip":101,"country":102,"countryCode":103,"cosmosGeoPoint":104,"geoPoint":109,"contacts":60},"HonorHealth","TERMINATED","Scottsdale","Arizona","85258","United States","US",{"type":105,"coordinates":106},"Point",[107,108],-111.89903,33.50921,{"lat":108,"lon":107},{"facility":111,"status":112,"city":113,"state":114,"zip":115,"country":102,"countryCode":103,"cosmosGeoPoint":116,"geoPoint":120,"contacts":60},"Cedars Sinai Medical Center","RECRUITING","Los Angeles","California","90048",{"type":105,"coordinates":117},[118,119],-118.24368,34.05223,{"lat":119,"lon":118},{"facility":122,"status":112,"city":113,"state":114,"zip":115,"country":102,"countryCode":103,"cosmosGeoPoint":123,"geoPoint":125,"contacts":60},"Cedars-Sinai Cancer at Cedars-Sinai Medical Center",{"type":105,"coordinates":124},[118,119],{"lat":119,"lon":118},{"facility":127,"status":112,"city":128,"state":114,"zip":129,"country":102,"countryCode":103,"cosmosGeoPoint":130,"geoPoint":134,"contacts":60},"UCSF Medical Center at Mission Bay","San Francisco","94158",{"type":105,"coordinates":131},[132,133],-122.41942,37.77493,{"lat":133,"lon":132},{"facility":136,"status":112,"city":137,"state":138,"zip":139,"country":102,"countryCode":103,"cosmosGeoPoint":140,"geoPoint":144,"contacts":60},"Smilow Cancer Hospital at Yale - New Haven","New Haven","Connecticut","06510",{"type":105,"coordinates":141},[142,143],-72.92816,41.30815,{"lat":143,"lon":142},{"facility":146,"status":112,"city":137,"state":138,"zip":139,"country":102,"countryCode":103,"cosmosGeoPoint":147,"geoPoint":149,"contacts":60},"Yale-New Haven Hospital- Yale Cancer Center",{"type":105,"coordinates":148},[142,143],{"lat":143,"lon":142},{"facility":151,"status":112,"city":137,"state":138,"zip":152,"country":102,"countryCode":103,"cosmosGeoPoint":153,"geoPoint":155,"contacts":60},"Smilow Cancer Hospital Phase 1 Unit","06511",{"type":105,"coordinates":154},[142,143],{"lat":143,"lon":142},{"facility":157,"status":112,"city":137,"state":138,"zip":152,"country":102,"countryCode":103,"cosmosGeoPoint":158,"geoPoint":160,"contacts":60},"Yale University",{"type":105,"coordinates":159},[142,143],{"lat":143,"lon":142},{"facility":162,"status":98,"city":163,"state":164,"zip":165,"country":102,"countryCode":103,"cosmosGeoPoint":166,"geoPoint":170,"contacts":60},"Holy Cross Hospital","Fort Lauderdale","Florida","33308",{"type":105,"coordinates":167},[168,169],-80.14338,26.12231,{"lat":169,"lon":168},{"facility":172,"status":112,"city":173,"state":174,"zip":175,"country":102,"countryCode":103,"cosmosGeoPoint":176,"geoPoint":180,"contacts":60},"St. Elizabeth Healthcare","Edgewood","Kentucky","41017",{"type":105,"coordinates":177},[178,179],-84.58189,39.01867,{"lat":179,"lon":178},{"facility":182,"status":112,"city":183,"state":174,"zip":184,"country":102,"countryCode":103,"cosmosGeoPoint":185,"geoPoint":189,"contacts":60},"University Medical Center, lnc.:DBA University of Louisville Hospital","Louisville","40202",{"type":105,"coordinates":186},[187,188],-85.75941,38.25424,{"lat":188,"lon":187},{"facility":191,"status":112,"city":183,"state":174,"zip":184,"country":102,"countryCode":103,"cosmosGeoPoint":192,"geoPoint":194,"contacts":60},"University of Louisville",{"type":105,"coordinates":193},[187,188],{"lat":188,"lon":187},{"facility":196,"status":112,"city":183,"state":174,"zip":184,"country":102,"countryCode":103,"cosmosGeoPoint":197,"geoPoint":199,"contacts":60},"UofL Health Brown Cancer Center",{"type":105,"coordinates":198},[187,188],{"lat":188,"lon":187},{"facility":201,"status":112,"city":202,"state":203,"zip":204,"country":102,"countryCode":103,"cosmosGeoPoint":205,"geoPoint":209,"contacts":60},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":105,"coordinates":206},[207,208],-86.78444,36.16589,{"lat":208,"lon":207},{"facility":211,"status":112,"city":212,"state":213,"zip":214,"country":102,"countryCode":103,"cosmosGeoPoint":215,"geoPoint":219,"contacts":60},"MD Anderson The Woodlands","Conroe","Texas","77384",{"type":105,"coordinates":216},[217,218],-95.45605,30.31188,{"lat":218,"lon":217},{"facility":221,"status":112,"city":222,"state":213,"zip":223,"country":102,"countryCode":103,"cosmosGeoPoint":224,"geoPoint":228,"contacts":60},"The University of Texas M. D. Anderson Cancer Center","Houston","77030",{"type":105,"coordinates":225},[226,227],-95.36327,29.76328,{"lat":227,"lon":226},{"facility":230,"status":112,"city":222,"state":213,"zip":223,"country":102,"countryCode":103,"cosmosGeoPoint":231,"geoPoint":233,"contacts":60},"U.T. MD Anderson Cancer Center",{"type":105,"coordinates":232},[226,227],{"lat":227,"lon":226},{"facility":235,"status":112,"city":222,"state":213,"zip":236,"country":102,"countryCode":103,"cosmosGeoPoint":237,"geoPoint":239,"contacts":60},"MD Anderson West Houston","77079",{"type":105,"coordinates":238},[226,227],{"lat":227,"lon":226},{"facility":241,"status":112,"city":242,"state":213,"zip":243,"country":102,"countryCode":103,"cosmosGeoPoint":244,"geoPoint":248,"contacts":60},"MD Anderson League City","League City","77573",{"type":105,"coordinates":245},[246,247],-95.09493,29.50745,{"lat":247,"lon":246},{"facility":250,"status":112,"city":251,"state":213,"zip":252,"country":102,"countryCode":103,"cosmosGeoPoint":253,"geoPoint":257,"contacts":60},"NEXT Oncology","San Antonio","78229",{"type":105,"coordinates":254},[255,256],-98.49363,29.42412,{"lat":256,"lon":255},{"facility":259,"status":112,"city":260,"state":213,"zip":261,"country":102,"countryCode":103,"cosmosGeoPoint":262,"geoPoint":266,"contacts":60},"MD Anderson","Sugar Land","77478",{"type":105,"coordinates":263},[264,265],-95.63495,29.61968,{"lat":265,"lon":264},{"facility":268,"status":112,"city":269,"state":270,"zip":271,"country":102,"countryCode":103,"cosmosGeoPoint":272,"geoPoint":276,"contacts":60},"Swedish Cancer Institute","Seattle","Washington","98104",{"type":105,"coordinates":273},[274,275],-122.33207,47.60621,{"lat":275,"lon":274},{"facility":278,"status":112,"city":269,"state":270,"zip":279,"country":102,"countryCode":103,"cosmosGeoPoint":280,"geoPoint":282,"contacts":60},"Swedish Medical Center","98122",{"type":105,"coordinates":281},[274,275],{"lat":275,"lon":274},{"facility":284,"status":98,"city":285,"state":286,"zip":287,"country":288,"countryCode":289,"cosmosGeoPoint":290,"geoPoint":294,"contacts":60},"Chris O'Brien Lifehouse","Camperdown","New South Wales","2050","Australia","AU",{"type":105,"coordinates":291},[292,293],151.17642,-33.88965,{"lat":293,"lon":292},{"facility":296,"status":112,"city":297,"state":298,"zip":299,"country":288,"countryCode":289,"cosmosGeoPoint":300,"geoPoint":304,"contacts":60},"Cancer Research South Australia","Adelaide","South Australia","5000",{"type":105,"coordinates":301},[302,303],138.59863,-34.92866,{"lat":303,"lon":302},{"facility":306,"status":112,"city":307,"state":308,"zip":309,"country":288,"countryCode":289,"cosmosGeoPoint":310,"geoPoint":314,"contacts":60},"Peter MacCallum Cancer Centre","Melbourne","Victoria","3000",{"type":105,"coordinates":311},[312,313],144.96332,-37.814,{"lat":313,"lon":312},{"facility":316,"status":112,"city":317,"state":308,"zip":318,"country":288,"countryCode":289,"cosmosGeoPoint":319,"geoPoint":323,"contacts":60},"Royal Melbourne Hospital","Parkville","3050",{"type":105,"coordinates":320},[321,322],144.95,-37.78333,{"lat":322,"lon":321},{"facility":325,"status":112,"city":326,"state":308,"zip":327,"country":288,"countryCode":289,"cosmosGeoPoint":328,"geoPoint":332,"contacts":60},"Western Health-Sunshine & Footscray Hospitals","St Albans","3021",{"type":105,"coordinates":329},[330,331],144.80049,-37.74496,{"lat":331,"lon":330},{"facility":334,"status":112,"city":335,"state":336,"zip":337,"country":288,"countryCode":289,"cosmosGeoPoint":338,"geoPoint":342,"contacts":60},"St. John of God Subiaco Hospital","Subiaco","Western Australia","6008",{"type":105,"coordinates":339},[340,341],115.8268,-31.9485,{"lat":341,"lon":340},{"facility":344,"status":112,"city":345,"state":346,"zip":347,"country":348,"countryCode":349,"cosmosGeoPoint":350,"geoPoint":354,"contacts":60},"Beijing Cancer hospital","Beijing","Beijing Municipality","100142","China","CN",{"type":105,"coordinates":351},[352,353],116.39723,39.9075,{"lat":353,"lon":352},{"facility":356,"status":112,"city":357,"state":358,"zip":359,"country":348,"countryCode":349,"cosmosGeoPoint":360,"geoPoint":364,"contacts":60},"SUN Yat-Sen University Cancer Center","Guangzhou","Guangdong","510060",{"type":105,"coordinates":361},[362,363],113.25,23.11667,{"lat":363,"lon":362},{"facility":366,"status":112,"city":367,"state":368,"zip":369,"country":348,"countryCode":349,"cosmosGeoPoint":370,"geoPoint":374,"contacts":60},"Jilin Province Tumor Hospital","Changchun","Jilin","130000",{"type":105,"coordinates":371},[372,373],125.32278,43.88,{"lat":373,"lon":372},{"facility":366,"status":112,"city":367,"state":368,"zip":376,"country":348,"countryCode":349,"cosmosGeoPoint":377,"geoPoint":379,"contacts":60},"132000",{"type":105,"coordinates":378},[372,373],{"lat":373,"lon":372},{"facility":381,"status":112,"city":382,"state":383,"zip":384,"country":348,"countryCode":349,"cosmosGeoPoint":385,"geoPoint":389,"contacts":60},"The First Affiliated Hospital of Xi'an Jiaotong University","Xi'an","Shaanxi","710061",{"type":105,"coordinates":386},[387,388],108.92861,34.25833,{"lat":388,"lon":387},{"facility":391,"status":112,"city":392,"state":393,"zip":394,"country":395,"countryCode":396,"cosmosGeoPoint":397,"geoPoint":401,"contacts":60},"Aichi Cancer Center Hospital","Nagoya","Aichi-ken","464-8681","Japan","JP",{"type":105,"coordinates":398},[399,400],136.90641,35.18147,{"lat":400,"lon":399},{"facility":403,"status":112,"city":404,"state":405,"zip":406,"country":395,"countryCode":396,"cosmosGeoPoint":407,"geoPoint":411,"contacts":60},"National Cancer Center Hospital East","Kashiwa","Chiba","277-8577",{"type":105,"coordinates":408},[409,410],139.97732,35.86224,{"lat":410,"lon":409},{"facility":413,"status":112,"city":414,"state":415,"zip":416,"country":395,"countryCode":396,"cosmosGeoPoint":417,"geoPoint":421,"contacts":60},"Kanagawa cancer center","Yokohama","Kanagawa","2418515",{"type":105,"coordinates":418},[419,420],139.65,35.43333,{"lat":420,"lon":419},{"facility":423,"status":112,"city":424,"state":425,"zip":426,"country":395,"countryCode":396,"cosmosGeoPoint":60,"geoPoint":60,"contacts":60},"National Cancer Center Hospital","Chuo-ku","Tokyo","104-0045",{"facility":428,"status":112,"city":429,"state":430,"zip":431,"country":432,"countryCode":60,"cosmosGeoPoint":433,"geoPoint":437,"contacts":60},"Seoul National University Bundang Hospital","Seongnam-si","Gyeonggi-do","13620","South Korea",{"type":105,"coordinates":434},[435,436],127.13778,37.43861,{"lat":436,"lon":435},{"facility":439,"status":112,"city":440,"state":441,"zip":442,"country":432,"countryCode":60,"cosmosGeoPoint":443,"geoPoint":447,"contacts":60},"Seoul National University Hospital","Seoul","Seoul-teukbyeolsi [seoul]","03080",{"type":105,"coordinates":444},[445,446],126.9784,37.566,{"lat":446,"lon":445},{"facility":449,"status":112,"city":440,"state":441,"zip":450,"country":432,"countryCode":60,"cosmosGeoPoint":451,"geoPoint":453,"contacts":60},"Severance Hospital, Yonsei University Health System","03722",{"type":105,"coordinates":452},[445,446],{"lat":446,"lon":445},{"facility":455,"status":112,"city":440,"state":441,"zip":456,"country":432,"countryCode":60,"cosmosGeoPoint":457,"geoPoint":459,"contacts":60},"Samsung Medical Center","06351",{"type":105,"coordinates":458},[445,446],{"lat":446,"lon":445},{"facility":461,"status":112,"city":462,"state":463,"zip":464,"country":432,"countryCode":60,"cosmosGeoPoint":465,"geoPoint":469,"contacts":60},"Kyungpook National University Chilgok Hospital","Daegu","Taegu-kwangyǒkshi","41404",{"type":105,"coordinates":466},[467,468],128.59111,35.87028,{"lat":468,"lon":467},{"facility":471,"status":112,"city":440,"state":60,"zip":472,"country":432,"countryCode":60,"cosmosGeoPoint":473,"geoPoint":475,"contacts":60},"Asan Medical Center","05505",{"type":105,"coordinates":474},[445,446],{"lat":446,"lon":445},{"type":477,"investigatorFullName":60,"investigatorTitle":60,"investigatorAffiliation":60,"oldNameTitle":60,"oldOrganization":60},"SPONSOR","100409050","phase-2-study-of-pf-07248144-in-advanced-or-metastatic-solid-tumors-100409050",false,"NCT04606446","Study of PF-07248144 in Advanced or Metastatic Solid Tumors","A PHASE 1\u002F2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS","KAT6","Inclusion Criteria:\n\n* Disease Characteristics - Breast, Prostate, and Lung Cancer\n* Part 1A (Monotherapy Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer, CRPC, or NSCLC that is intolerant or resistant to standard therapy or for which no standard therapy is available.\n* Part 1B, Part 1C, Part 1D and Part 1E (Combination Dose Escalation) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of treatment with an endocrine therapy and CDK4\u002F6 inhibitor in the advanced or metastatic setting.\n* Part 2A (ER+HER2- breast cancer 2L+, monotherapy) Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer. Participants must have progressed after at least 1 prior line of CDK4\u002F6 inhibitor and 1 line of endocrine therapy.\n* Part 2B (ER+HER2- breast cancer 2-4L, combination with fulvestrant) Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4\u002F6 inhibitor and at least 1 prior line of endocrine therapy.. Participants must not have received more than 3 prior lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant.\n* Part 2D (ER+HER2- breast cancer 2-4L, combination with PF-07220060 (CDK4i) and fulvestrant):\n\nHistological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4\u002F6 inhibitor and at least 1 prior line of endocrine therapy.\n\n* Participants must have not received more than 3 lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have but are not required to have prior treatment with fulvestrant.\n* Part 2E (ER+HER2- breast cancer 2-4L, combination with vepdegestrant): Histological or cytological diagnosis of advanced or metastatic ER+HER2- breast cancer. Participants must have progressive disease after at least 1 prior line of a CDK4\u002F6 inhibitor and at least 1 prior line of endocrine therapy; Participants must have not received more than 3 lines of systemic therapies including up to 1 line of cytotoxic chemotherapy for visceral disease in advanced or metastatic setting; Participants may have received fulvestrant\n* Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of ER-positive tumor (≥1% positive stained cells) based on most recent tumor biopsy utilizing an assay consistent with local standards.\n* Participants with ER+HER2- advanced or metastatic breast cancer must have documentation of HER2-negative tumor: HER2-negative tumor is determined as immunohistochemistry score 0\u002F1+ or negative by in situ hybridization (FISH\u002FCISH\u002FSISH\u002FDISH) defined as a HER2\u002FCEP17 ratio \\\u003C2 or for single probe assessment a HER2 copy number \\\u003C4.\n* Female participants with ER+HER2- advanced or metastatic breast cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause by treatment with the approved LHRH agonist such as goserelin, leuprolide or equivalent agents to induce chemical menopause.\n* Female participants with ER+HER2- advanced or metastatic breast cancer of nonchildbearing potential must meet at least 1 criteria of achieving postmenopausal status.\n* Participants must have at least 1 measurable lesion as defined by RECIST version 1.1 that has not been previously irradiated.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status PS 0 or 1\n* Female or male patients aged ≥ 18 years (Japan ≥ 20 years) (South Korea ≥ 19 years).\n* Adequate renal, liver, and bone marrow function.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for adverse events (AEs) not constituting a safety risk by investigator judgment.\n\nExclusion Criteria:\n\n* Unmanageable ascites (limited medical treatment to control ascites is permitted, but all participants with ascites require review by sponsor's medical monitor).\n* Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.\n* Major surgery, radiation therapy, or systemic anti-cancer therapy within 3 weeks prior to study entry.\n* Prior irradiation to \\>25% of the bone marrow.\n* ECG clinically relevant abnormalities (eg, QTc \\>470 msec, complete LBBB, second\u002Fthird degree AV block, ST elevation or EKG changes suggesting myocardial infarction or active myocardia ischemia).\n* Therapeutic anticoagulation. However, low molecular weight heparin is allowed. Vitamin K antagonists or factor Xa inhibitors may be allowed following discussion with the Sponsor.\n* Known or suspected hypersensitivity or severe allergy to active ingredient\u002Fexcipients of PF-07248144.\n* Active inflammatory GI disease, refractory and unresolved chronic diarrhea or previous gastric resection, lap band surgery or other GI conditions and surgeries that may significantly alter the absorption of PF-07248144 tablets. Gastroesophageal reflux disease under treatment is allowed.\n* Pregnant or breastfeeding female participants.","ALL","18 Years",{"count":489,"type":490},320,"ESTIMATED","INTERVENTIONAL",[493],"PHASE2","This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents",[496,497,498],"Locally Advanced or Metastatic ER+ HER2- Breast Cancer","Locally Advanced or Metastatic Castration-resistant Prostate Cancer","Locally Advanced or Metastatic Non-small Cell Lung Cancer",[500],"Solid tumors","2026-04-15",{"date":503,"type":504},"2026-04-16","ACTUAL",{"date":506,"type":504},"2020-11-16",{"date":508,"type":490},"2029-08-10",{"name":5,"class":6},44]